Nothing Special   »   [go: up one dir, main page]

DI BELLO et al., 1994 - Google Patents

Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light‐chain epitopes

DI BELLO et al., 1994

View PDF
Document ID
9895294083980101834
Author
DI BELLO I
Poulain B
Shone C
Tauc L
Dolly J
Publication year
Publication venue
European journal of biochemistry

External Links

Snippet

mAbs were produced in mice against highly purified, renatured light chain (LC) of botulinum neurotoxin A (BoNT A) that was immobilised on nitrocellulose to avoid the undesirable use of toxoids. Subcutaneous implants of relatively high amounts (up to 10 μg each) of LC …
Continue reading at febs.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani

Similar Documents

Publication Publication Date Title
DI BELLO et al. Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light‐chain epitopes
US7462699B2 (en) BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
Hopper et al. Individual antigenic specificity of immunoglobulin
Halpern et al. Cloning and expression of functional fragment C of tetanus toxin
Vestweber et al. A 42K outer-membrane protein is a component of the yeast mitochondrial protein import site
Motté et al. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies
US9963502B2 (en) Antibody that specifically binds partially processed or unprocessed neurotoxin polypeptides
JPH06502994A (en) Proteins with modified epitopes and methods for their production
Atassi et al. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies
US6667158B1 (en) Antibodies against type a botulinum neurotoxin
Seckler et al. Anti-peptide antibodies and proteases as structural probes for the lactose/proton transporter of Escherichia coli: a loop around amino acid residue 130 faces the cytoplasmic side of the membrane
US20070258992A1 (en) Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
US20130345398A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
Poulain et al. Antibodies against rat brain vesicle‐associated membrane protein (synaptobrevin) prevent inhibition of acetylcholine release by tetanus toxin or botulinum neurotoxin type B
Little et al. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies
Foran et al. Blockade by botulinum neurotoxin B of catecholamine release from adrenochromaffin cells correlates with its cleavage of synaptobrevin and a homolog present on the granules
US8236513B2 (en) Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin A peptides
Bidart et al. Antigenic determinants on human choriogonadotropin alpha-subunit. I. Characterization of topographic sites recognized by monoclonal antibodies.
KR101983216B1 (en) Antibodies for determining an activity of botulinum toxin and a method for using the same
Choumet et al. Neutralization of lethal potency and inhibition of enzymatic activity of a phospholipase A2 neurotoxin, crotxin, by non‐precipitating antibodies (Fab)
US20100273211A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
Lin et al. Antibodies against the light chain of tetanus toxin in human sera
Roy The amino acid sequence of the peptide containing the thiol group of creatine kinase from normal and dystrophic chicken breast muscle. Comparison of some of the immunological properties of the antibodies developed in rabbits against these enzymes
US20060141572A1 (en) Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
Poulain et al. Raven zyxwvutsrqponmlkjihgfedcb